Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors

Oncology

Volumn 66, Issue 4, 2004, Pages 253-259

  Kakolyris, S ^a   Souglakos, J ^b   Kouroussis, C ^b   Androulakis, N ^b   Samonis, G ^b   Vardakis, N ^b   Amarantidis, K ^a   Agelaki, S ^b   Mavroudis, D ^b   Xenidis, N ^b   Georgoulias, V ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Capecitabine; Oxaliplatin; Phase i; Solid tumors

Indexed keywords

CAPECITABINE; DIPHENOXYLATE; LOPERAMIDE; OXALIPLATIN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DYSESTHESIA; EDEMA; ERYTHEMA; FEMALE; FLUSHING; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; REMISSION; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WORLD HEALTH ORGANIZATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; DEOXYCYTIDINE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOUTH MUCOSA; NAUSEA; NEOPLASMS; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME; VOMITING;

EID: 3042594276     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078324     Document Type: Article

References (30)

1. Raymond E, Faivre S, Woynarowski JM, Chaney SG: Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998;25(suppl 5):4-12.
2. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 1996;52:1855-1865.
3. Woynarowski JM, Chapman WG, Napier C: Oxaliplatin effects on naked and intracellular DNA (abstract A2083). Proc Am Assoc Cancer Res 1997;38:311.
4. Bleiberg H: Oxaliplatin (L-OHP): A new reality in colorectal cancer. Br J Cancer 1998;7(suppl 4):1-3.
5. Cvitkovic E: Ongoing and unsaid on oxaliplatin: The hope. Br J Cancer 1996;77(suppl 4):8-11.
6. Extra JM, Marty M, Brienza S, Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25(suppl 5):13-22.
7. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303.
8. Miwa M, Ura M, Nishida M, et al: Design of a novel fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumor by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, in press.
9. Ishikawa T, Sekiguchi F, Fukase Y, et al: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activity in tumors in human cancer xenografts. Cancer Res 1998:58:685-690.
10. Jones A, Harris AL: New developments in angiogenesis: A major mechanism for tumor growth and target for therapy. Cancer J 1998;4:209-217.
11. Ishikawa T, Utoh M, Sawada N, et al: Capecitabine, a new oral fluoropyrimidine carbamate, selectively delivers fluorouracil to tumor tissues in human cancer xenografts. Biochem Pharmacol 1998;55:1091-1097.
12. Cao S, Lu K, Ishisuka H, et al: Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors (abstr). Proc Am Soc Clin Oncol 1997;16:226a.
13. Twelves C, Budman DR, Creaven PJ, et al: Pharmacokinetics and pharmacodynamics of capecitabine in two phase I studies (abstr). Proc Am Soc Clin Oncol 1996;15:479.
14. Van Cutsem E, Findlay M, Osterwalder B, et al: Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized Phase II study. J Clin Oncol 2000;18:1337-1345.
15. Hoff M, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282-2292.
16. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circardian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 1990;82:1046-1050.
17. Miller AB, Hoogstraten BB, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
18. Ishitsuka H, Miwa M, Ishikawa T, et al: Capecitabine: An orally available fluoropyrimidine with tumor selective activity (abstr 2426). Proc Am Soc Cancer Res 1995;36.
19. Schuller J, Cassidy J, Reigner B, et al: Tumor selectivity of Xeloda in colorectal cancer patients (abstr 797). Proc Am Soc Clin Oncol 1997;16.
20. Fox SB, Westwood M, Moghaddam A, et al: The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer 1996;73:275-280.
21. Nishina T, Hyodo I, Moriwaki T, et al: The ratio of thymidine phosphorylase (TP) to dihydropyrimidine dehydrogenase (DPD) levels in tumor tissues is predictive of response to 5′-deoxy-5-fluorouridine (an intermediate metabolite of capecitabine): A prospective study in patients with metastatic gastric cancer (abstr 602). Proc Am Soc Clin Oncol 2002;21.
22. Raymond E, Buquet-Fagot C, Djelloul S, et al: Antitumor activity of oxaliplatin in combination with fluorouracil and the thymidine phosphorylase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-cancer Drugs 1997;8:876-885.
23. Mathe G, Kidani Y, Segiguchi M, et al: Oxalato-platinum or L-OHP, a third generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cisplatin and carboplatinum. Biomed Pharmacother 1989;43:237-250.
24. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
25. Tabernero J, Brunet R, Butts C, et al: Capecitabine and oxaliplatin in combination (Xelox) as first-line treatment for patients with metastatic colorectal cancer: Results of an international, multicenter, phase II trial (abstr 531). Proc Am Soc Clin Oncol 2002;21.
26. De Santis S, Zeuli M, Di Costanzo F, et al: Oxaliplatin and capecitabine in advanced colorectal cancer: A dose-finding trial (abstr 559). Proc Am Soc Clin Oncol 2001;20.
27. Shields AF, Zalupski MM, Marshall JL, et al: A phase II trial of oxaliplatin and capecitabine in patients with advanced colorectal cancer (abstr 568). Proc Am Soc Clin Oncol 2002;21.
28. Aschele C, Friso ML, Pucciarelli S, et al: A phase I-II study of weekly oxaliplatin (OXA), 5-fluorouracil (FU) continuous infusion (CI) and preoperative radiotherapy (RT) in locally advanced rectal cancer (LARC) (abstr 527). Proc Am Soc Clin Oncol 2002;21.
29. Jin M, Chen Q, Cheng FQ, et al: Oxaliplatin (OXA) in combination with LV5FU2 in Chinese patients with advanced gastric cancer (AGC) (abstr 558). Proc Am Soc Clin Oncol 2002;21.
30. Comella P, Massida B, Farris A, et al: Oxaliplatin plus leucovorin/fluorouracil I.V. bolus (OXAFAFU) versus irinotecan plus leucovorin/fluorouracil i.v. bolus (IRIFAFU) as firstline treatment of advanced colorectal carcinoma (ACC): SICOG 0103 randomized study (abstr 645). Proc Am Soc Clin Oncol 2002;21.